JPS6256490A - 高純度メチルコバラミンの製造方法 - Google Patents
高純度メチルコバラミンの製造方法Info
- Publication number
- JPS6256490A JPS6256490A JP19601985A JP19601985A JPS6256490A JP S6256490 A JPS6256490 A JP S6256490A JP 19601985 A JP19601985 A JP 19601985A JP 19601985 A JP19601985 A JP 19601985A JP S6256490 A JPS6256490 A JP S6256490A
- Authority
- JP
- Japan
- Prior art keywords
- methylcobalamin
- lower aliphatic
- reaction mixture
- aliphatic ketone
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 title claims abstract description 38
- 235000007672 methylcobalamin Nutrition 0.000 title claims abstract description 38
- 239000011585 methylcobalamin Substances 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims abstract description 28
- 235000000639 cyanocobalamin Nutrition 0.000 claims abstract description 14
- 239000011666 cyanocobalamin Substances 0.000 claims abstract description 14
- 229960002104 cyanocobalamin Drugs 0.000 claims abstract description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000011541 reaction mixture Substances 0.000 claims abstract description 11
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 claims abstract 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 16
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- AAMWFMOHRYFSEU-UHFFFAOYSA-N methanol;propan-2-one;hydrate Chemical compound O.OC.CC(C)=O AAMWFMOHRYFSEU-UHFFFAOYSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 6
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 235000004867 hydroxocobalamin Nutrition 0.000 abstract description 3
- 239000011704 hydroxocobalamin Substances 0.000 abstract description 3
- 229960001103 hydroxocobalamin Drugs 0.000 abstract description 3
- 238000007069 methylation reaction Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 3
- 239000000499 gel Substances 0.000 abstract description 2
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000007599 discharging Methods 0.000 abstract 1
- 230000001035 methylating effect Effects 0.000 abstract 1
- 230000011987 methylation Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- -1 aliphatic ketones Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000013076 target substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002156 adsorbate Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19601985A JPS6256490A (ja) | 1985-09-06 | 1985-09-06 | 高純度メチルコバラミンの製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19601985A JPS6256490A (ja) | 1985-09-06 | 1985-09-06 | 高純度メチルコバラミンの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6256490A true JPS6256490A (ja) | 1987-03-12 |
| JPH0572919B2 JPH0572919B2 (enrdf_load_stackoverflow) | 1993-10-13 |
Family
ID=16350868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19601985A Granted JPS6256490A (ja) | 1985-09-06 | 1985-09-06 | 高純度メチルコバラミンの製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6256490A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014510134A (ja) * | 2011-05-30 | 2014-04-24 | インターキム ソシエダッド アノニマ デ キャピタル バリアブレ | メチルコバラミンの合成プロセス |
-
1985
- 1985-09-06 JP JP19601985A patent/JPS6256490A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014510134A (ja) * | 2011-05-30 | 2014-04-24 | インターキム ソシエダッド アノニマ デ キャピタル バリアブレ | メチルコバラミンの合成プロセス |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0572919B2 (enrdf_load_stackoverflow) | 1993-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100234930B1 (ko) | 2-0-알파-d글루코피라노실-l-아스코르브산고 함유물의 제조방법 | |
| WO1984000759A1 (fr) | Derives de desoxyuridine, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| JPH05247078A (ja) | 糖化合物、シアル酸含有糖鎖類生合成阻害剤、その製造方法、並びに新規な中間体 | |
| JPS61140599A (ja) | ５’‐メチルチオ‐５’‐デオキシアデノシンと長鎖アルキルスルホン酸との塩 | |
| JPS6256490A (ja) | 高純度メチルコバラミンの製造方法 | |
| JPH08143590A (ja) | 高純度メチルコバラミンの製造方法 | |
| JP3315158B2 (ja) | グルタチオンの精製法 | |
| US5223500A (en) | Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate | |
| JPS6256491A (ja) | 高純度メチルコバラミンの製造法 | |
| JPH07113024B2 (ja) | ピロロキノリンキノンの精製方法 | |
| US2709669A (en) | Process for separating vitamin b12 active substances from contaminants | |
| JPS62242692A (ja) | モラノリン誘導体の製造法 | |
| JPS6337635B2 (enrdf_load_stackoverflow) | ||
| JPH0826020B2 (ja) | ジデオキシイノシンの精製方法 | |
| JPH0631306B2 (ja) | シチジン―５′―ジリン酸コリン１水和物結晶の製造法 | |
| JPS6377890A (ja) | Ｌ−アスコルビン酸−２−リン酸エステルの精製法 | |
| JPS61115093A (ja) | モラノリン誘導体の製法 | |
| JP3053510B2 (ja) | Ｄ−キロ−イノシトールの製造法 | |
| JP3643603B2 (ja) | 精製フラクトオリゴ糖の製造方法 | |
| EP0045415B1 (en) | Di-l-cysteine l-malate and process for the production thereof | |
| JPH0267256A (ja) | カルニチンおよびカルニチンニトリルの単離精製法 | |
| JP3433301B2 (ja) | ５，６，７，８−テトラヒドロ−ｄ−ネオプテリンの有機酸塩の製造法 | |
| US3461113A (en) | Process for recovering flavin-adenine dinucleotide | |
| JPH0812693A (ja) | アスコルビン酸誘導体の製造法 | |
| SU557794A1 (ru) | Способ очистки рутина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |